Several members of the thiosemicarbazone family were identified by an in silico screen of the NCI60 anti-cancer drug screen (NSC319725, NSC319726, NSC328784) as compounds that had preferential activity in mutant p53 cells lines while displaying relatively little toxicity in cell lines containing wild-type p53. The gene discussed is TP53; the disease is cancer.